Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

Ashley Communications celebrates 20 years of medical communications

Looks forward with new business wins, including AbbVie and Merck & Co accounts

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

- PMLiVE

Sanofi and Merck & Co finalise vaccine alliance split

Dissolve Sanofi Pasteur MSD after poor sales growth

- PMLiVE

Keytruda closes in on Opdivo’s lead in Hodgkin lymphoma

KEYNOTE-087 trial shows an overall response rate of 69 percent

- PMLiVE

NICE green lights Keytruda for second-line lung cancer

Merck & Co's oncology treatment backed in draft guidance for NSCLC

- PMLiVE

Keytruda gets priority FDA review for biomarker-positive tumours

Merck & Co’s immuno-oncology drug used for colorectal cancer

- PMLiVE

EU citizens are living longer, but not always in good health

Report finds huge inequalities between and within countries despite higher life expectancy

- PMLiVE

Sanofi launches ‘Highs & Lows’ diabetes awareness campaign

Highlights impact of emotional and psychological factors on effective self-management

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links